crizotinib + imatinib + osimertinib

This is a combination therapy consisting of three small-molecule tyrosine kinase inhibitors (TKIs): crizotinib, imatinib, and osimertinib. Each drug targets distinct molecular pathways involved in cancer cell proliferation and survival. Crizotinib inhibits ALK, ROS1, and MET tyrosine kinases; imatinib inhibits BCR-ABL, c-Kit (stem cell factor receptor), and PDGF receptors; while osimertinib selectively targets mutant forms of the epidermal growth factor receptor (EGFR), including T790M resistance mutations. This triple combination has been used in rare clinical scenarios to treat patients with multiple concurrent malignancies or complex resistance mechanisms—such as EGFR-mutant non-small cell lung cancer (NSCLC) with acquired MET amplification alongside gastrointestinal stromal tumor (GIST)—where single-agent or dual-agent therapies are insufficient. The regimen requires careful therapeutic drug monitoring due to significant potential for pharmacokinetic interactions and toxicity[1][3][6].

Other names

crizotinib + imatinib + osimertinib